Close
View the Institutional Research Information System profiles for each of our researchers below:
View our publications by year:
- 2021
- Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon Skene, Kashfia Chowdhury, Steve Hibbert, Huw Morris, Patricia Limousin, Dilan Athauda, Camille B Carroll, Michele T Hu, Monty Silverdale, Gordon W Duncan, Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie | Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a
multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study | BMJ Open Neurology, Volume 11, Issue 5, 12 May 2021 - Daniel F P Larkin, Kashfia Chowdhury, Jennifer M Burr, Mathew Raynor, Matthew Edwards, Stephen J Tuft, Catey Bunce, Emilia Caverly, Caroline Doré | EFFECT OF CORNEAL CROSS-LINKING vs STANDARD CARE ON KERATOCONUS PROGRESSION IN YOUNG PATIENTS: THE KERALINK RANDOMIZED CONTROLLED TRIAL | PMID: 33892046 | DOI: 10.1016/j.ophtha.2021.04.019
- Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon Skene, Kashfia Chowdhury, Steve Hibbert, Huw Morris, Patricia Limousin, Dilan Athauda, Camille B Carroll, Michele T Hu, Monty Silverdale, Gordon W Duncan, Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie | Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a
- 2020
- Ruth Brauer, Li Wei, Tiantian Ma, Dilan Athauda, Christine Girges, Nirosen Vijiaratnam, Grace Auld, Cate Whittlesea, Ian Wong, Tom Foltynie | Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes | Brain, Volume 143, Issue 10, October 2020, Pages 3067–3076
- Hakim‐Moulay Dehbi David M. Lowe John O'Quigley. Early phase dose‐finding trials in virology
- Alexander C.Day PhD; Jennifer M.Burr MD; Kate Bennett MSc; Catey Bunce DSc; Caroline J.Doré BSc; Gary S.Rubin PhD; Mayank A.Nanavaty PhD; Kamaljit S.Balaggan PhD; Mark R.Wilkins MD. Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT): A Randomized Noninferiority Trial.
- 2019
Alexis Jones, Patrick Muller, Caroline J Dore, Felicia Ikeji, Emilia Caverly, Kashfia Chowdhury, David A Isenberg, Caroline Gordon, Michael R Ehrenstein (2019). Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. BMJ.
Hobbs, A., Moyes, A., Baliga, R., Ghedia, D., Ochiel, R., Sylvestre, Y., Doré, C., Chowdhury, K., Maclagan, K., Quartly, H., Sofat, R., Smit, A., Schreiber, B., Coghlan, J. and MacAllister, R. (2019). Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. British Journal of Pharmacology.
Lewis C, Hutchinson J C, Riddington M, Hill M, Arthurs O J, Fisher J, Wade A, Doré C J, Chitty L S & Sebire N J.
. https://doi.org/10.3310/hta23460Adrian J. Hobbs, Amie J. Moyes, Reshma S. Baliga, Dipa Ghedia, Rachel Ochiel, Yvonne Sylvestre, Caroline J. Doré, Kashfia Chowdhury, Kate Maclagan, Harriet L. Quartly, Reecha Sofat, Angelique Smit, Benjamin E. Schreiber, J. Gerry Coghlan, Raymond J. MacAllister. Neprilysin inhibition for pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled, proof-of-concept trial. https://doi.org/10.1111/bph.14621
- 2018
- Tan, M., Wright, D., Syngelaki, A., Akolekar, R., Cicero, S., Janga, D., Singh, M., Greco, E., Wright, A., Maclagan, K., Poon, L. and Nicolaides, K. (2018). Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound in Obstetrics & Gynecology, 51(6), pp.743-750.
- Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Aviles-Olmos, I., Chowdhury, K., Skene, S., Limousin, P. and Foltynie, T. (2018). Post hoc analysis of the Exenatide-PD trial-Factors that predict response. European Journal of Neuroscience, 49(3), pp.410-421.
- Athauda, D., Maclagan, K., Budnik, N., Zampedri, L., Hibbert, S., Skene, S., Chowdhury, K., Aviles-Olmos, I., Limousin, P. and Foltynie, T. (2018). What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson’s Disease: A Post Hoc Analysis. Journal of Parkinson's Disease, 8(2), pp.247-258.
- Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, Poon LC, Nicolaides KH.
- Taylor SA, Mallett S, Bhatnagar G, Baldwin-Cleland R, Bloom S, Gupta A, Hamlin PJ, Hart AL, Higginson A, Jacobs I, McCartney S, Miles A, Murray CD, Plumb AA, Pollok RC, Punwani S, Quinn L, Rodriguez-Justo M, Shabir Z, Slater A, Tolan D, Travis S17, Windsor A, Wylie P, Zealley I, Halligan S, METRIC study investigators.
- 2017
- Rolnik, D., Wright, D., Poon, L., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., Molina, F., Persico, N., Jani, J., Plasencia, W., Papaioannou, G., Tenenbaum-Gavish, K., Meiri, H., Gizurarson, S., Maclagan, K. and Nicolaides, K. (2017). Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. New England Journal of Medicine, 377(7), pp.613-622.
- Athauda, D., Maclagan, K., Skene, S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., Li, Y., Aviles-Olmos, I., Warner, T., Limousin, P., Lees, A., Greig, N., Tebbs, S. and Foltynie, T. (2017). Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. The Lancet, 390(10103), pp.1664-1675.
- Spencer R, Ambler G, Brodszki J, Diemert A, Figueras F, Gratacós E, Hansson SR, Hecher K, Huertas-Ceballos A, Marlow N, Marsál K, Morsing E, Peebles D, Rossi C, Sebire NJ, Timms JF, David AL; EVERREST Consortium.. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. BMC Pregnancy Childbirth. 2017 Jan 23;17(1):43. doi: 10.1186/s12884-017-1226-7.
- The INFANT Collaborative Group. Computerised interpretation of fetal heart rate during labour (INFANT): a randomised controlled trial. Lancet 2017; published online March 21. http://dx.doi.org/10.1016/S0140-6736(17)30568-8.
- Daniel L. Rolnik, M.D., David Wright, Ph.D., Liona C. Poon, M.D., Neil O'Gorman, M.D., Argyro Syngelaki, Ph.D., Catalina de Paco Matallana, M.D., Ranjit Akolekar, M.D., Simona Cicero, M.D., Deepa Janga, M.D., Mandeep Singh, M.D., Francisca S. Molina, M.D., Nicola Persico, M.D., Jacques C. Jani, M.D., Walter Plasencia, M.D., George Papaioannou, M.D., Kinneret Tenenbaum‑Gavish, M.D., Hamutal Meiri, Ph.D., Sveinbjorn Gizurarson, Ph.D., Kate Maclagan, Ph.D., and Kypros H. Nicolaides, M.D. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia N Engl J Med 2017; 377:613-622. DOI: 10.1056/NEJMoa1704559
- China L, Skene SS, Shabir Z, Maini AA, Sylvestre Y, Bennett K, Bevan S, O'Beirne J, Forrest E, Portal J, Ryder S, Wright G, Gilroy DW, O'Brien A. Administration of Albumin Solution Increases Serum Levels of Albumin in Patients with Chronic Liver Failure in a Single-arm Feasibility Trial. Clinical Gastroenterology and Hepatology, Article in press; Published online: 11 Sep 2017 https://www.ncbi.nlm.nih.gov/pubmed/28911947
- China L, Maini AA, Skene SS, Shabir Z, Sylvestre Y, Colas RA, Ly L, Salles NB, Belloti V, Dalli J, Gilroy DW, O'Brien A. Albumin Counteracts Immune-suppressive effects of lipid mediators in patients with advanced liver disease. Clinical Gastroenterology and Hepatology, 2017 Aug 28; Article in press; Published online: 30 Aug 2017 https://www.ncbi.nlm.nih.gov/pubmed/28859868
- 2016
- Cohen H, Hunt BJ, Efthymiou M, Arachchillage DRJ, Mackie IM, Clawson S, Sylvestre Y, Machin SJ, Bertolaccini ML, Ruiz-Castellano M, Muirhead N, Doré CJ, Khamashta M, Isenberg DA, for the Raps trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematology 2016;3:e426-36.
- China L, Muirhead N, Skene SS, Shabir Z, De Maeyer RPH, Maini AAN, Gilroy DW, O'Brien AJ. ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial. BMJ Open 2016; 6: e010132
- Goldberg AJ, Zaidi R, Thomson C, Doré CJ, Skene SS, Cro S, Round J, Molloy A, Davies M, Karski M, Kim L, Cooke P, on behalf of the TARVA study group. Total ankle replacement versus arthrodesis (TARVA): protocol for a multicentre randomised controlled trial. BMJ Open 2016;6:e012716.
- O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open 2016; 6: e011801.
- 2015
- Birchall MA, Schilder AG, Janes S, Ansari T, Tebbs S, Sheridan R, Ezra R, Round J, Seifalian A, Carvalho C, Sandhu G, Culme-Seymour E, Mason C, Lowdell M. RegenVOX: a Phase I/II clinical trial of stem cell-based tissue-engineered laryngeal implants. Cytotherapy 2015; 17(6):S69.
- Cohen H, Doré CJ, Clawson S, Hunt BJ, Isenberg D, Khamashta M, Muirhead N on behalf of the RAPS Trial Protocol Collaborators. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus 2015, 24(10):1087-1094. DOI: 10.1177/0961203315581207
- Cohen H, Hunt B, Efythmiou M, Arachchillage D, Ruiz M, Clawson S, Muirhead N, Sylvestre Y, Machin S, Bertolaccini ML, Doré CJ, Mackie I, Isenberg D, Khamashta M. RAPS (rivaroxaban in antiphospholipid syndrome): a prospective, randomized controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. (Abstract) Journal of Thrombosis and Haemostasis 2015; 13(SI2):84.
- Day AC, Burr JM, Bunce C, Doré CJ, Sylvestre Y, Wormald RPL, Round J, McCudden V, Rubin G, Wilkins MR, on behalf of the FACT Group. Randomised, single masked non-inferiority trial of femtosecond laser-assisted versus manual phacoemulsification cataract surgery for adults with visually significant cataract: the FACT trial protocol. BMJ Open 2015; 5:e010381.
- 2014
- Taylor S, Mallet S, Bhatnagar G, Cloom S, Gupta A, Halligan S, Hamlin J, Hart A, Higginson A, Jacobs I, McCartney S, Morris S, Muirhead N, Murray C, Punwani S, Rodriguez-Justo M, Slater A, Travis S, Tolan D, Windsor A, Wyliw P, Zealey I. METRIC (MrEnterography or uLTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. BMC Gastroenterology 2014; 14:142.
- 2013
- Cohen H, Doré CJ, Clawson S, Hunt BJ, Khamashta M, Machin SJ, Muirhead N. RAPS: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. (Abstract) Journal of Thrombosis and Haemostasis 2013; 11(SI2):860.
All rights reserved.